Key Highlights

  • Ginkgo Bioworks shares are down about 4% in pre-market trading.
  • Q2 2026 revenue came in at $20.2 million, missing estimates of $24.1 million.
  • Revenue fell 48% year over year, though it was down a smaller 3% excluding a one-time item from the prior year.
  • Cash burn improved to $45 million in the quarter from $53 million a year earlier.
  • The company reaffirmed full-year 2026 cash burn guidance of $125 million to $150 million.

Shares Decline on Revenue Miss

Ginkgo Bioworks is trading lower today after the synthetic biology company reported second-quarter revenue that fell short of Wall Street expectations. Shares declined as much as 4.06% to $8.99 in pre-market trading, a continuation of Wednesday's session in which the stock closed flat.

Revenue for the quarter came in at $20.2 million, down 48% year over year and below the $24.1 million analysts had forecast. Excluding a $7.5 million non-cash item from a prior year biometric agreement, revenue was down a more modest 3% year over year. The company's operating loss came in at $58.5 million for the quarter.

Cash Burn Narrows Despite Weaker Top Line

On a more positive note, cash burn narrowed to $45 million in the second quarter, compared with $53 million a year earlier, and was better than the company's own guidance of $56 million to $58 million. Cash burn for the first half of the year totaled $87 million, and the company reaffirmed full-year 2026 cash burn guidance of $125 million to $150 million.

Ginkgo reported $302 million in cash and cash equivalents plus $87 million in restricted cash, and raised $17 million via its at-the-market equity program in the quarter.

About Ginkgo Bioworks

Ginkgo Bioworks is a Boston based biotechnology company that has built a horizontal platform for cell engineering and biosecurity. Operating through its Cell Engineering and Biosecurity segments, the company enables customers across pharmaceutical, agriculture, industrial, food, consumer, and government and defense sectors to design, optimize, and scale organisms using tools like functional genomics, AI models, and automated foundry infrastructure.

Segment Performance

Revenue softness was broad-based but weighed particularly on the Cell Engineering segment, which serves pharmaceutical, agriculture, and industrial biotech customers whose budgets have tightened amid a difficult funding environment for smaller biotech firms. The Biosecurity segment, which includes pandemic preparedness and biosurveillance offerings, provided a more stable revenue base during the quarter, though it did not fully offset the decline elsewhere in the business.

Management pointed to the launch of new lower-cost testing services and continued expansion of automated lab infrastructure as evidence that the company is investing through the downturn in customer spending, positioning itself to capture demand once biotech funding conditions improve.

Strategic Highlights

The company highlighted several strategic developments during the quarter, including expansion of the Nebula autonomous lab in Boston to 105 racks, new autonomous lab deals with the Massachusetts Institute of Technology, Maryland, and Northwestern under an NSF program, work with the Pacific Northwest National Lab, and the launch of a new lower-cost ADME testing service positioned to compete with other contract research organizations such as WuXi.

Conclusion

Ginkgo Bioworks' second-quarter revenue miss reflects continued softness across smaller biotech customer spending, even as the company continues to narrow its cash burn and reaffirm its full-year targets. Investors will likely watch for signs of stabilizing demand from biotech customers in the coming quarters.

Why is Ginkgo Bioworks stock down today?

Shares are trading lower after the company reported second-quarter 2026 revenue of $20.2 million, below analyst estimates of $24.1 million.

Did Ginkgo Bioworks improve its cash burn?

Yes. Cash burn narrowed to $45 million in the second quarter from $53 million a year earlier, and came in better than the company's own guidance.

What is Ginkgo Bioworks' full-year cash burn guidance?

The company reaffirmed full-year 2026 cash burn guidance of $125 million to $150 million.

This article is for informational purposes only and does not constitute financial, investment, or trading advice. Readers should conduct their own research or consult a licensed financial advisor before making any investment decisions.